HomeCompareSQZ vs XYLD

SQZ vs XYLD: Dividend Comparison 2026

SQZ yields 459.77% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SQZ wins by $32296.80M in total portfolio value
10 years
SQZ
SQZ
● Live price
459.77%
Share price
$0.44
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32296.82M
Annual income
$22,619,113,625.24
Full SQZ calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — SQZ vs XYLD

📍 SQZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSQZXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SQZ + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SQZ pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SQZ
Annual income on $10K today (after 15% tax)
$39,080.46/yr
After 10yr DRIP, annual income (after tax)
$19,226,246,581.45/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, SQZ beats the other by $19,226,243,845.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SQZ + XYLD for your $10,000?

SQZ: 50%XYLD: 50%
100% XYLD50/50100% SQZ
Portfolio after 10yr
$16148.42M
Annual income
$11,309,558,422.13/yr
Blended yield
70.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SQZ right now

SQZ
Analyst Ratings
4
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$4.00
+819.5% upside vs current
Range: $4.00 — $4.00
Altman Z
-22.9
Piotroski
2/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SQZ buys
0
XYLD buys
0
No recent congressional trades found for SQZ or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSQZXYLD
Forward yield459.77%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$32296.82M$25.3K
Annual income after 10y$22,619,113,625.24$3,219.02
Total dividends collected$31438.26M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: SQZ vs XYLD ($10,000, DRIP)

YearSQZ PortfolioSQZ Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$56,677$45,977.01$10,818$1,098.39+$45.9KSQZ
2$304,181$243,536.41$11,738$1,222.51+$292.4KSQZ
3$1,547,006$1,221,532.43$12,774$1,364.64+$1.53MSQZ
4$7,461,354$5,806,058.08$13,944$1,527.86+$7.45MSQZ
5$34,154,829$26,171,179.52$15,270$1,715.87+$34.14MSQZ
6$148,508,521$111,962,854.47$16,775$1,933.09+$148.49MSQZ
7$613,881,121$454,977,003.60$18,490$2,184.87+$613.86MSQZ
8$2,414,527,788$1,757,674,987.75$20,450$2,477.63+$2414.51MSQZ
9$9,044,589,126$6,461,044,393.43$22,697$2,819.19+$9044.57MSQZ
10$32,296,823,990$22,619,113,625.24$25,280$3,219.02+$32296.80MSQZ

SQZ vs XYLD: Complete Analysis 2026

SQZStock

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Full SQZ Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this SQZ vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SQZ vs SCHDSQZ vs JEPISQZ vs OSQZ vs KOSQZ vs MAINSQZ vs QYLDSQZ vs JEPQSQZ vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.